Zevra Therapeutics Inc (FRA:1GDA)
€ 4.44 -0.04 (-0.89%) Market Cap: 181.24 Mil Enterprise Value: 173.39 Mil PE Ratio: 0 PB Ratio: 3.99 GF Score: 52/100

Q4 2022 Zevra Therapeutics Inc Earnings Call Transcript

Mar 07, 2023 / 01:30PM GMT
Release Date Price: €4.93 (-1.00%)
Operator

Good day, and welcome to the Zevra Therapeutics Fourth Quarter and Full Year 2022 Update Call. (Operator Instructions) Please be advised that today's call is being recorded.

I want to hand the call over to Zevra's Vice President of Investor Relations and Corporate Communications, Nichol Ochsner. Thank you. You may begin.

Nichol L. Ochsner
Zevra Therapeutics, Inc. - VP of IR & Corporate Communications

Good morning. Thank you for joining us today to review Zevra's Fourth quarter and full year 2022 clinical operational progress and financial results. A few housekeeping items before we start. I invite you to view the webcast slides and the press release, both of which were issued this morning and can be found in the Investors section of our website.

As outlined on Slide 2, during today's presentation, we will be making several forward-looking statements. These forward-looking statements include, but are not limited to, the clinical and regulatory path for arimoclomol, AZSTARYS, revenue milestones and expected revenue from the French EAP

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot